PDSB
PDS Biotechnology Corporation
5.21
USD
This page is just a preview of the data found in TrendSpider’s full version
PDS Biotechnology Corporation stock is up 14.51% since 30 days ago. The next earnings date is Mar 26, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 8 December’s closed higher than November. In the last 3 Unusual Options Trades, there were 3 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 10 Nov 15:52 | 19 Jan, 2024 | 7.50 | 1376 | ||
| 10 Nov 18:47 | 19 Jan, 2024 | 2.50 | 532 | ||
| 14 Nov 15:14 | 17 May, 2024 | 5.00 | 83 |
PDS Biotechnology Corporation focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials.
